Search

EHA in EU-funded project on voluntary plasma collection capacity in Europe

EHA to participate in an EU-funded project on “Strengthening voluntary non-remunerated plasma collection capacity in Europe” (SUPPLY)

Context: Plasma shortage 

Plasma-derived medicinal products (PDMPs) are used to treat a variety of rare, chronic, and potentially life-threatening conditions including immune deficiencies, immune-mediated peripheral…

Read more

EHA donates €250,000 to Médecins Sans Frontières

The EHA Board is actively implementing support actions to hematologists and hematology patients in Ukraine and to those who are forced to leave the country.

Read more

EHA: Bridging Breakthroughs in Hematology

The European Hematology Association (EHA) has undergone a remarkable transformation over the past two years, positioning itself as a future-ready organization dedicated to addressing the needs of the European hematology community.

Read more

EHA Research Mobility Grants

The call for applications is now open

EHA strives to develop the career of young scientists by supporting mobility and facilitating a visit to a research group in another institute.

Read more

Addition of obinutuzumab (GA101) or rituximab to chlorambucil improves outcomes for elderly patients with chronic lymphocytic leukemia (CLL) and co-existing medical conditions (comorbidities)

CLL is the most common leukemia in the western world. Many CLL patients are elderly and have comorbidities rendering them ineligible for aggressive standard treatments.

Read more

Exciting developments in Lymphoma (lymphnode cancer) and Myeloma (plasma cell cancer) to be presented at European Hematology Congress in Stockholm, June 13-16, 2013

Myeloma, until recently a fatal bone marrow malignancy with a short survival time, is now turning into a chronic disease.

Read more

Code of Conduct

The guidelines below govern the publication of, and commentary on the EHA Hematology Hub. Please read through them before participating. 1. Abide by the rules that normally apply.

Read more